Company Filing History:
Years Active: 2001
Title: Frank Narjes: Innovator in Polypeptide Production and Purification
Introduction
Frank Narjes is a notable inventor based in Ariccia, Italy. He has made significant contributions to the field of molecular biology, particularly in the production and purification of polypeptides. His work is essential for advancing therapeutic agents against Hepatitis C virus (HCV).
Latest Patents
Frank Narjes holds a patent for a methodology to produce, purify, and assay polypeptides with the proteolytic activity of the HCV NS3 protease. This innovative process allows for the expression and isolation of polypeptides in a pure, catalytically active form. The methodology is crucial for discovering NS3 protease inhibitors and determining the three-dimensional structure of the NS3 protease. Additionally, the invention outlines the necessary chemical and physical conditions for the proteolytic activity of these polypeptides. It also introduces new compositions of matter, including expression vectors that contain nucleotide sequences capable of expressing the polypeptides in cultured cells. Furthermore, the invention defines new compounds suitable for measuring proteolytic activity, which are useful in developing therapeutic agents against HCV.
Career Highlights
Frank Narjes is associated with the Istituto di Ricerche di Biologia Molecolare S.p.a., where he continues to contribute to research and innovation in molecular biology. His work has implications for the development of treatments for viral infections, particularly those caused by HCV.
Collaborations
Frank has collaborated with notable colleagues, including Christian Steinkühler and Antonello Pessi. These collaborations have further enhanced the research and development efforts in the field of molecular biology.
Conclusion
Frank Narjes is a distinguished inventor whose work in polypeptide production and purification is paving the way for new therapeutic solutions against HCV. His contributions are vital for advancing medical research and improving treatment options for patients.